BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Tian D, Tian M, Han G, Li JL. Increased glucocorticoid receptor activity and proliferation in metastatic colon cancer. Sci Rep 2019;9:11257. [PMID: 31375708 DOI: 10.1038/s41598-019-47696-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
2 Singh P, Singh A, Shah S, Vataliya J, Mittal A, Chitkara D. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme. Mol Pharm 2020;17:4040-66. [PMID: 32902291 DOI: 10.1021/acs.molpharmaceut.0c00709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Nickel AC, Picard D, Qin N, Wolter M, Kaulich K, Hewera M, Pauck D, Marquardt V, Torga G, Muhammad S, Zhang W, Schnell O, Steiger HJ, Hänggi D, Fritsche E, Her NG, Nam DH, Carro MS, Remke M, Reifenberger G, Kahlert UD. Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses. Biomed Pharmacother 2021;144:112278. [PMID: 34628166 DOI: 10.1016/j.biopha.2021.112278] [Reference Citation Analysis]
4 Susmi TF, Rahman Khan MM, Rahman A, Mahmud S, Saleh MA, Reza MA, Rahi MS. In vitro antioxidant and cytotoxicity activities and in silico anticancer property of methanolic leaf extract of Leucas indica. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.100963] [Reference Citation Analysis]
5 Wang PF, Qiu HY, He Y, Zhu HL. Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019). Expert Opin Ther Pat 2020;30:795-805. [PMID: 32945222 DOI: 10.1080/13543776.2020.1825686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863 [PMID: 34007126 DOI: 10.3748/wjg.v27.i17.1847] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Liang X, Wu P, Yang Q, Xie Y, He C, Yin L, Yin Z, Yue G, Zou Y, Li L, Song X, Lv C, Zhang W, Jing B. An update of new small-molecule anticancer drugs approved from 2015 to 2020. Eur J Med Chem 2021;220:113473. [PMID: 33906047 DOI: 10.1016/j.ejmech.2021.113473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Al-Sanea MM, Obaidullah AJ, Shaker ME, Chilingaryan G, Alanazi MM, Alsaif NA, Alkahtani HM, Alsubaie SA, Abdelgawad MA. A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights. Molecules 2021;26:E412. [PMID: 33466812 DOI: 10.3390/molecules26020412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhu XR, Peng SQ, Wang L, Chen XY, Feng CX, Liu YY, Chen MB. Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer. Cell Death Dis 2021;12:918. [PMID: 34620839 DOI: 10.1038/s41419-021-04201-w] [Reference Citation Analysis]
10 Pook H, Pauklin S. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4834. [PMID: 34638318 DOI: 10.3390/cancers13194834] [Reference Citation Analysis]
11 Sevgin B, Coban MN, Rencuzogullari Ö, Coker-gurkan A, Obakan-yerlikaya P, Uysal Onganer P, Arisan ED. AMPK Is the Crucial Target for the CDK4/6 Inhibitors Mediated Therapeutic Responses in PANC-1 and MIA PaCa-2 Pancreatic Cancer Cell Lines. Stresses 2021;1:48-68. [DOI: 10.3390/stresses1010005] [Reference Citation Analysis]
12 Al-Owaidi DS, Algazally ME, Alawaad AS. Genetic Association of rs2237572 Cyclin-Dependent Kinase 6 Gene with Breast Cancer in Iraq. Indian J Clin Biochem 2021;36:304-11. [PMID: 34220005 DOI: 10.1007/s12291-020-00895-5] [Reference Citation Analysis]
13 Zhang YB, Jiang Y, Wang J, Ma J, Han S. Evaluation of core serous epithelial ovarian cancer genes as potential prognostic markers and indicators of the underlying molecular mechanisms using an integrated bioinformatics analysis. Oncol Lett 2019;18:5508-22. [PMID: 31612059 DOI: 10.3892/ol.2019.10884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Bengtsson A, Andersson R, Rahm J, Ganganna K, Andersson B, Ansari D. Organoid technology for personalized pancreatic cancer therapy. Cell Oncol (Dordr). 2021;44:251-260. [PMID: 33492660 DOI: 10.1007/s13402-021-00585-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters GJ, Giovannetti E, Diana P. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers (Basel) 2021;13:4389. [PMID: 34503199 DOI: 10.3390/cancers13174389] [Reference Citation Analysis]
16 Jiggens E, Mortoglou M, Grant GH, Uysal-Onganer P. The Role of CDK4 in the Pathogenesis of Pancreatic Cancer. Healthcare (Basel) 2021;9:1478. [PMID: 34828525 DOI: 10.3390/healthcare9111478] [Reference Citation Analysis]
17 Hussain Qureshi MF, Shah M, Lakhani M, Abubaker ZJ, Mohammad D, Farhan H, Zia I, Tafveez R, Khan ST, Rubina G, Shamim M, Ghulam H. Gene signatures of cyclin-dependent kinases: a comparative study in naïve early and advanced stages of lung metastasis breast cancer among pre- and post-menopausal women. Genes Cancer 2021;12:1-11. [PMID: 33868579 DOI: 10.18632/genesandcancer.209] [Reference Citation Analysis]
18 Ferreira HJ, de Almeida EM, da Silva WMB, Teixeira EH, do Nascimento Neto LG. Molecular Mechanisms Involved in the Antitumor Activity of Isolated Lectins from Marine Organisms: A Systematic Review. Curr Drug Targets 2020;21:616-25. [PMID: 31763966 DOI: 10.2174/1389450120666191122113850] [Reference Citation Analysis]
19 Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, Rudek MA, Doyle LA, Nelkin B, Maitra A, Azad NS; ETCTN-9231 Study Team. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clin Transl Sci 2020;13:1178-88. [PMID: 32738099 DOI: 10.1111/cts.12802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kciuk M, Gielecińska A, Mujwar S, Mojzych M, Kontek R. Cyclin-dependent kinases in DNA damage response. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Park H, Lee JY, Park S, Song G, Lim W. Developmental toxicity and angiogenic defects of etoxazole exposed zebrafish (Danio rerio) larvae. Aquat Toxicol 2019;217:105324. [PMID: 31634662 DOI: 10.1016/j.aquatox.2019.105324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
22 Khan T, Seddon AM, Dalgleish AG, Khelwatty S, Ioannou N, Mudan S, Modjtahedi H. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. Oncol Rep 2020;44:2581-94. [PMID: 33125153 DOI: 10.3892/or.2020.7822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mortazavi M, Moosavi F, Martini M, Giovannetti E, Firuzi O. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol 2022;:103749. [PMID: 35728737 DOI: 10.1016/j.critrevonc.2022.103749] [Reference Citation Analysis]
24 Campbell GJ, Hands EL, Van de Pette M. The Role of CDKs and CDKIs in Murine Development. Int J Mol Sci 2020;21:E5343. [PMID: 32731332 DOI: 10.3390/ijms21155343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mottaghi S, Abbaszadeh H. The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives. Phytother Res 2021. [PMID: 34498311 DOI: 10.1002/ptr.7270] [Reference Citation Analysis]
26 Huang Y, Zhu H, Ji X, Chen Y, Zhang Y, Huang R, Xie J, Dong P. TBX3 knockdown suppresses the proliferation of hypopharyngeal carcinoma FaDu cells by inducing G1/S cell cycle arrest and apoptosis. Oncol Lett 2020;19:113-20. [PMID: 31897121 DOI: 10.3892/ol.2019.11089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Yang M, Qin Q, Zhu J, Guo Y, Yin T, Wu H, Wang C. Long noncoding RNA ITGB2-AS1 promotes growth and metastasis through miR-4319/RAF1 axis in pancreatic ductal adenocarcinoma. J Cell Physiol 2020. [PMID: 31957875 DOI: 10.1002/jcp.29471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhang C, Huang L, Xiong J, Xie L, Ying S, Jia Y, Yao Y, Song X, Zeng Z, Yuan J. Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway. PLoS One 2021;16:e0247752. [PMID: 33661942 DOI: 10.1371/journal.pone.0247752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hossian AKMN, Mackenzie GG, Mattheolabakis G. Combination of miR‑143 and miR‑506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclin‑dependent kinases. Oncol Rep 2021;45:2. [PMID: 33649787 DOI: 10.3892/or.2021.7953] [Reference Citation Analysis]
30 Marak BN, Dowarah J, Khiangte L, Singh VP. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents. European Journal of Medicinal Chemistry 2020;203:112571. [DOI: 10.1016/j.ejmech.2020.112571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Mandal R, Becker S, Strebhardt K. Targeting CDK9 for Anti-Cancer Therapeutics. Cancers (Basel) 2021;13:2181. [PMID: 34062779 DOI: 10.3390/cancers13092181] [Reference Citation Analysis]
32 Muhamad P, Panrit L, Chaijaroenkul W, Na-Bangchang K. Cytotoxicity, Cell Cycle Arrest, and Apoptosis Induction Activity of Ethyl-p-methoxycinnamate in Cholangiocarcinoma Cell. Asian Pac J Cancer Prev 2020;21:927-34. [PMID: 32334452 DOI: 10.31557/APJCP.2020.21.4.927] [Reference Citation Analysis]